Current anticoagulant therapy--unmet clinical needs (Q35159120)

6 August 2017

1 reference

title

Current anticoagulant therapy--unmet clinical needs (English)

1 reference

6 August 2017

1 reference

1 reference

Jack Hirsh

1

1 reference

6 August 2017

publication date

1 July 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

109 Suppl 1

1 reference

6 August 2017

page(s)

S1-8

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

6 August 2017

1 reference

7 January 2021

Molecular and cellular biology of blood coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

1 reference

7 January 2021

Oral anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

The emerging role of low-molecular-weight heparin in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Low-molecular-weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Protection of factor Xa from neutralization by the heparin-antithrombin complex

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

An update on clinical and basic aspects of the protein C anticoagulant pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Anticoagulant repertoire of the hookworm Ancylostoma caninum

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Kinetics of the inhibition of thrombin by hirudin.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

New anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Bivalirudin: a new generation antithrombotic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Clinical outcomes of bivalirudin for ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Soluble plasma thrombomodulin levels in patients with chronic myeloproliferative disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on so

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Importance of factor Xa in determining the procoagulant activity of whole-blood clots

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900250-0

7 January 2021

10.1016/S0049-3848(03)00250-0

Identifiers

DOI

1 reference

6 August 2017

1 reference